In 2017, Li and Banham’s group innovatively generated a TCR mimic antibody, T1-116C (259), that recognize a p53-derived epitope selectively displayed on MHC class I only by cancer cells, inducing tumor regression in mice with breast cancer xenografts.607 Later in 2019, Wang’s group developed another p53-specific TCR-like antibody, P1C1TM (260), that can induce cellular cytotoxicity towards cancer cells bearing p53 mutations dependent on selective antibody.608 Bispecific antibodies are another type of specific antibody that shows promise in cancer immunotherapy. This evidence concerns the gene TP53 and neoplasm.